Skip to main
CMPS
CMPS logo

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 15 analyst ratings
Strong Buy
Strong Buy 67%
Buy 27%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways PLC is well-positioned for growth due to its innovative approach in addressing treatment-resistant depression (TRD) through its proprietary COMP360 psilocybin therapy, which exhibits superior efficacy compared to existing treatments like Spravato, which has surpassed $1 billion in annual revenue. The company’s phase 2b data suggest that maintaining similar efficacy while optimizing dosing frequency could enhance COMP360's market appeal and commercial potential, supported by a favorable safety profile. With the broader momentum in the psychedelics market, there is a promising outlook for COMP360, particularly given its demonstrated rapid reductions in depressive and anxious symptoms, indicating a strong demand for effective mental health therapies.

Bears say

Compass Pathways's stock outlook is negatively impacted by several fundamental concerns regarding its clinical development and regulatory environment. The uncertainty surrounding the efficacy of its lead product, COMP360, especially given the context of Lykos Therapeutics' negative AdComm and subsequent CRL, raises questions about the company's ability to achieve clinically meaningful benefits in its phase III trials. Additionally, the heightened scrutiny from the FDA and potential failure to commercialize may result in significant downside risks to earnings estimates, which could lead to considerable stock price volatility for Compass Pathways.

COMPASS Pathways (CMPS) has been analyzed by 15 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 27% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Strong Buy based on their latest research and market trends.

According to 15 analysts, COMPASS Pathways (CMPS) has a Strong Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.